Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.
OBJECTIVE:Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown. We determined whether metformin administration affects lipoprotein subfractions...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4726568?pdf=render |
| _version_ | 1818152666845413376 |
|---|---|
| author | Ruben N Eppinga Minke H T Hartman Dirk J van Veldhuisen Chris P H Lexis Margery A Connelly Erik Lipsic Iwan C C van der Horst Pim van der Harst Robin P F Dullaart |
| author_facet | Ruben N Eppinga Minke H T Hartman Dirk J van Veldhuisen Chris P H Lexis Margery A Connelly Erik Lipsic Iwan C C van der Horst Pim van der Harst Robin P F Dullaart |
| author_sort | Ruben N Eppinga |
| collection | DOAJ |
| description | OBJECTIVE:Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown. We determined whether metformin administration affects lipoprotein subfractions 4 months after ST-segment elevation MI (STEMI). Second, we assessed associations of lipoprotein subfractions with left ventricular ejection fraction (LVEF) and infarct size 4 months after STEMI. METHODS:371 participants without known diabetes participating in the GIPS-III trial, a placebo controlled, double-blind randomized trial studying the effect of metformin (500 mg bid) during 4 months after primary percutaneous coronary intervention for STEMI were included of whom 317 completed follow-up (clinicaltrial.gov Identifier: NCT01217307). Lipoprotein subfractions were measured using nuclear magnetic resonance spectroscopy at presentation, 24 hours and 4 months after STEMI. (Apo)lipoprotein measures were obtained during acute STEMI and 4 months post-STEMI. LVEF and infarct size were measured by cardiac magnetic resonance imaging. RESULTS:Metformin treatment slightly decreased LDL cholesterol levels (adjusted P = 0.01), whereas apoB remained unchanged. Large LDL particles and LDL size were also decreased after metformin treatment (adjusted P<0.001). After adjustment for covariates, increased small HDL particles at 24 hours after STEMI predicted higher LVEF (P = 0.005). In addition, increased medium-sized VLDL particles at the same time point predicted a smaller infarct size (P<0.001). CONCLUSION:LDL cholesterol and large LDL particles were decreased during 4 months treatment with metformin started early after MI. Higher small HDL and medium VLDL particle concentrations are associated with favorable LVEF and infarct size. |
| first_indexed | 2024-12-11T13:58:21Z |
| format | Article |
| id | doaj.art-da41169d007d4d34830bd0124158c753 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T13:58:21Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-da41169d007d4d34830bd0124158c7532022-12-22T01:03:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01111e014571910.1371/journal.pone.0145719Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.Ruben N EppingaMinke H T HartmanDirk J van VeldhuisenChris P H LexisMargery A ConnellyErik LipsicIwan C C van der HorstPim van der HarstRobin P F DullaartOBJECTIVE:Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown. We determined whether metformin administration affects lipoprotein subfractions 4 months after ST-segment elevation MI (STEMI). Second, we assessed associations of lipoprotein subfractions with left ventricular ejection fraction (LVEF) and infarct size 4 months after STEMI. METHODS:371 participants without known diabetes participating in the GIPS-III trial, a placebo controlled, double-blind randomized trial studying the effect of metformin (500 mg bid) during 4 months after primary percutaneous coronary intervention for STEMI were included of whom 317 completed follow-up (clinicaltrial.gov Identifier: NCT01217307). Lipoprotein subfractions were measured using nuclear magnetic resonance spectroscopy at presentation, 24 hours and 4 months after STEMI. (Apo)lipoprotein measures were obtained during acute STEMI and 4 months post-STEMI. LVEF and infarct size were measured by cardiac magnetic resonance imaging. RESULTS:Metformin treatment slightly decreased LDL cholesterol levels (adjusted P = 0.01), whereas apoB remained unchanged. Large LDL particles and LDL size were also decreased after metformin treatment (adjusted P<0.001). After adjustment for covariates, increased small HDL particles at 24 hours after STEMI predicted higher LVEF (P = 0.005). In addition, increased medium-sized VLDL particles at the same time point predicted a smaller infarct size (P<0.001). CONCLUSION:LDL cholesterol and large LDL particles were decreased during 4 months treatment with metformin started early after MI. Higher small HDL and medium VLDL particle concentrations are associated with favorable LVEF and infarct size.http://europepmc.org/articles/PMC4726568?pdf=render |
| spellingShingle | Ruben N Eppinga Minke H T Hartman Dirk J van Veldhuisen Chris P H Lexis Margery A Connelly Erik Lipsic Iwan C C van der Horst Pim van der Harst Robin P F Dullaart Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. PLoS ONE |
| title | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. |
| title_full | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. |
| title_fullStr | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. |
| title_full_unstemmed | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. |
| title_short | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. |
| title_sort | effect of metformin treatment on lipoprotein subfractions in non diabetic patients with acute myocardial infarction a glycometabolic intervention as adjunct to primary coronary intervention in st elevation myocardial infarction gips iii trial |
| url | http://europepmc.org/articles/PMC4726568?pdf=render |
| work_keys_str_mv | AT rubenneppinga effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT minkehthartman effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT dirkjvanveldhuisen effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT chrisphlexis effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT margeryaconnelly effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT eriklipsic effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT iwanccvanderhorst effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT pimvanderharst effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial AT robinpfdullaart effectofmetformintreatmentonlipoproteinsubfractionsinnondiabeticpatientswithacutemyocardialinfarctionaglycometabolicinterventionasadjuncttoprimarycoronaryinterventioninstelevationmyocardialinfarctiongipsiiitrial |